Unleashing the Power of Multiomics: Unraveling the Molecular Landscape of Peripheral Neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
PubMed 40126913 · doi:10.1002/acn3.70019
What was done
This narrative review summarizes the evolution of genetic and multiomic tools used to evaluate peripheral neuropathies. It reviews traditional genetic approaches (linkage analysis, Sanger sequencing, FISH, PCR) alongside contemporary technologies (genome-wide association studies, targeted gene panels, whole-exome and whole-genome sequencing, long-read and single-cell sequencing, RNA sequencing, and proteomics) and discusses their clinical translation.
What was found
The abstract reports no primary experimental or quantitative trial data. It notes that peripheral neuropathies affect over 20 million individuals in the United States, with approximately one-third classified as idiopathic. The review outlines how next-generation sequencing and multiomics have accelerated variant discovery and challenged previous assumptions of pathogenicity compared to older diagnostic methods.
Why it matters
Integrating multiomic technologies may improve diagnostic yield, elucidate disease mechanisms, and identify therapeutic targets for idiopathic and genetically complex peripheral neuropathies.
Limits
The paper is a non-systematic narrative review providing no novel patient data, effect estimates, or pooled diagnostic metrics. The abstract explicitly notes ongoing difficulties in standardizing multiomic platforms and establishing clinical guidelines for routine medical practice.
Cited by
- supports Approximately 20 million individuals in the United States suffer from peripheral neuropathy.
- supports Around 30 million people in the United States suffer from some form of peripheral neuropathy.